Skip to main content

Table 6 Demographic characteristics and clinical findings according to the cut-off ELABELA levels in predicting CLL

From: Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?

VariablesELABELA (ng/ml)p
≤5.34
N = 14
> 5.34
N = 28
Age (years)63.7 ± 8.363.9 ± 10.60.948
Gender
 Female4 (28.6)10 (35.7)0.908
 Male10 (71.4)18 (64.3)
Disease duration (months)30 (2–72)24 (2–84)0.398
Stage
 07 (25.0)0.231
 16 (42.9)10 (35.7)
 24 (28.6)6 (21.4)
 32 (14.3)4 (14.3)
 42 (14.3)1 (3.6)
DC
 Negative8 (57.1)26 (92.9)0.011*
 Positive4 (28.6)1 (3.6)
 Weak positive2 (14.3)1 (3.6)
p53
 Negative3 (50.0)12 (80.0)0.401
 Positive3 (50.0)3 (20.0)
DEL13q
 Negative1 (25.0)4 (40.0)0.999
 Positive3 (75.0)6 (60.0)
Haemoglobin (g/dL)12 ± 2.212.7 ± 2.20.327
WBCs (×103/μL)29.6 (5.8–128.7)25.3 (6.4–131)0.539
Neutrophils (×103/μL)5.6 (0.7–8)5.5 (0.6–11.5)0.831
Lymphocytes (× 103/μL)24.3 (5–123)17.5 (5.2–116.5)0.496
Platelets (×103/μL)200 (81–463)200 (24–350)0.800
  1. Numerical variables are presented as mean ± standard deviation or median (min-max) according to normality distribution. Categorical variables are presented as number (%)
  2. * P < 0.05 indicates statistical significance
  3. Abbreviations: CLL Chronic lymphocytic leukaemia, WBC White blood cell